Lipid-Coated Hybrid Nanoparticles for Enhanced Bacterial Biofilm Penetration and Antibiofilm Efficacy

Hiang Wee Lee, Sharad Kharel, and Say Chye Joachim Loo*

Cite This: ACS Omega 2022, 7, 35814−35824

ABSTRACT: Up to 80% of all infections are biofilm-mediated and they are often challenging to treat as the underlying bacterial cells can become 100- to 1000-fold more tolerant toward antibiotics. Antibiotic-loaded nanoparticles have gained traction as a potential drug delivery system to treat biofilm infections. In particular, lipid-coated hybrid nanoparticles (LCHNPs) were investigated on their capability to deliver antibiotics into biofilms. In this study, LCHNPs composed of a poly(lactic-co-glycolic acid) (PLGA) core and dioleoyl-3-trimethylammonium propane (DOTAP) lipid shell were developed and loaded with vancomycin (Van). In vitro antibacterial and antibiofilm tests were performed to evaluate the antimicrobial efficacy of the LCHNPs. LCHNPs were successfully fabricated with high vancomycin encapsulation and loading efficiencies, and exhibited enhanced antibacterial effects against planktonic *Staphylococcus aureus* USA300 when compared against Free-Van and Van-PLGANPs. When used to treat USA300 biofilms, Van-LCHNPs eradicated up to 99.99% of the underlying biofilm cells, an effect which was not observed for Free-Van and Van-PLGANPs. Finally, we showed that by possessing a robust DOTAP shell, LCHNPs were able to penetrate deeply into the biofilms.

1. INTRODUCTION

Antibiotic-resistant infections are emerging as one of the most critical public health challenges today. In a report published by the Centre for Disease Control and Prevention (CDC) in 2019, it was estimated that 2.8 million antibiotic-resistant infections and more than 35,000 deaths occur each year in the United States. The number of infections is expected to increase to 10 million annually by 2050. It should be realized that infections that are impossible to treat are no longer a distant threat—it has already become a reality. While most antibiotic-resistant infections are still treatable today, they often necessitate the usage of second- or third-line antibiotic treatments, which often induce side effects that may prolong care and recovery for patients.

The biofilm way of life has been identified as a key strategy employed by bacteria to become more tolerant toward antibiotics; in fact, it was estimated that 65–80% of all infections were biofilm-mediated, highlighting the enormous clinical impact of biofilms on society. Biofilms are generally represented as an immobile population of bacteria cells embedded within a matrix that is attached to a surface. The matrix is formed by extracellular polymeric substances (EPSs) that are secreted by the bacteria cells. When bacteria, such as *Staphylococcus aureus* (*S. aureus*), enter the biofilm state, they become capable of withstanding hostile environments, such as starvation and antibiotic treatments, and cause chronic diseases. Upon entering the biofilm state, the underlying bacterial cells could tolerate antibiotic concentrations up to 100–1000 times the concentrations typically used to eradicate planktonic bacteria. Apart from acting as a diffusion barrier to antibiotics, certain components in the EPS could deactivate antibiotics, rendering them ineffective. As a consequence of the inability of existing antibiotics to properly eradicate biofilms, biofilm-associated infections tend to be recurring and life-threatening.

Methicillin-resistant *S. aureus* (MRSA) remains as a leading cause of death and morbidity due to infection, despite many years of infection control efforts. In fact, MRSA strains have been identified as an urgent threat to public health by the US CDC. Listed as one of the tough-to-treat ESRAPE pathogens, MRSA is ill-famed for causing recurring, long-term skin wound and soft tissue infections in the clinical setting. To complicate treatments further, MRSA can form sturdy biofilms at infection sites, rendering several antibiotic treatments
ineffective. Thus, there is a serious and urgent need to develop alternative treatments to overcome the various mechanisms employed by bacteria biofilms to render current antibiotics ineffective.

The use of nanoparticulate antibiotic delivery systems has been widely explored and showed promising therapeutic effects against bacterial cells in various modes of living. In particular, lipid-coated hybrid nanoparticles (LCHNPs) have garnered interest as a promising antibiotic delivery system. These particles adopt a core–shell structure, with the core often being an organic polymer surrounded by a lipid shell. By merits of the lipid shell, such as promoting the fusion of nanoparticles with the bacterial membrane, LCHNPs are postulated to have enhanced affinity toward bacterial cells, resulting in enhanced antibacterial effects. 12,13 We previously reported that when antibiotics were encapsulated in LCHNPs, there was a reduction in the minimum inhibitory concentration (MIC) of certain antibiotics by as much as 32-fold when the LCHNPs were used to treat planktonic cells. Yet, despite the remarkable antibacterial efficacy against planktonic cells, the same LCHNPs were unable to completely eradicate biofilms. 7 In a more recent study, LCHNPs loaded with ampicillin were used to treat protozoa infected with Enterococcus faecalis in an intracellular infection model. When compared to unencapsulated ampicillin, the ampicillin-loaded LCHNPs were able to boost the survivability of protozoa cells by up to 400% while the release of ampicillin also significantly reduced the quantity of intracellular bacterial cells. 14 While these prior studies explored the potential of LCHNPs in treating planktonic and intracellular bacterial infections, the potential of LCHNPs in treating biofilm infections remains unexplored.

In this study, we investigated the potential of LCHNPs in treating MRSA-USA300 biofilms. It was hypothesized that the presence of a cationic lipid coating in LCHNPs helps to enhance the penetration of these nanoparticles into biofilms, resulting in enhanced antibiofilm effects. In particular, we optimized the fabrication of vancomycin-loaded LCHNPs with a poly(lactic-co-glycolic acid) PLGA core and a dioleoyl-3-trimethylammonium propane (DOTAP) shell through a double emulsion solvent evaporation approach. The resulting nanoparticles were determined to have high encapsulation and loading efficiencies for vancomycin, despite it being a hydrophilic antibiotic. Furthermore, antibacterial tests showed that the vancomycin-loaded LCHNPs exhibited enhanced antibacterial and antibiofilm effects when compared to free vancomycin and nonlipid-coated, vancomycin-loaded PLGA nanoparticles. Finally, we verified our hypothesis by performing a biofilm penetration study with LCHNPs of various DOTAP:PLGA ratios. Through this, we concluded that the presence of a robust lipid layer exhibiting a strong positive charge is required to achieve enhanced penetration into USA300 biofilms. The main novelty of this study is the use of a well-optimized fabrication process to obtain antibiotic-loaded LCHNPs capable of eradicating up to 99.99% of biofilm cells. This contrasted with our prior study which used a different fabrication process and the resulting LCHNPs were unable to completely eradicate biofilms, even at high concentrations of antibiotic-loaded LCHNPs.

2. RESULTS AND DISCUSSION

2.1. Fabrication and Optimization of LCHNPs. In this study, LCHNPs were prepared using a simple emulsification technique. LCHNPs could be thought to consist of a polymeric PLGA core surrounded by a layer of lipid, DOTAP. By varying the DOTAP-to-PLGA ratio, LCHNPs with various encapsulation efficiencies (EEs), loading efficiencies (LEs), and ζ-potentials could be achieved (Table 1).

From Table 1, several observations could be drawn on the effects of the masses of PLGA and DOTAP used on the characteristics of the resulting LCHNPs. A comparison between LCHNP60:10 and LCHNP120:10 highlighted that a higher quantity of PLGA used during fabrication was associated with an increase in vancomycin EE, and a decrease in LE and ζ-potential. The increase in EE from 26.12 to 44.19% with higher PLGA quantity was consistent with several published studies. 15,16 These studies stated that an increase in PLGA quantity used during fabrication led to an increase in the core size of the nanoparticles, allowing for more vancomycin molecules to be encapsulated. A decrease in LE from 49.34 to 40.79 µg/mg was observed when a higher quantity of PLGA was used. With an increase in the nanoparticle core size, there is also an increase in the mass of each NP, which likely explains the reduction of LE since LE is inversely proportional to the mass of nanoparticles. Also, the stronger negative ζ-potential of −26.37 mV for LCHNP120:10 as compared to −9.58 mV for LCHNP60:10 was due to the increased viscosity of the overall emulsion, and thus resulted in poor fabrication of the nanoparticles.

A comparison between LCHNP60:10 and LCHNP60:20 revealed that the higher mass of DOTAP used in LCHNP60:20 was associated with an increase in EE, LE, and ζ-potential. Baek et al. suggested that hydrophilic drugs, such as vancomycin, tend to localize on the surface of hydrophobic PLGA nanoparticles. By incorporating a layer of lipid onto PLGA nanoparticles, hydrophilic drugs could be
trapped between the PLGA core and lipid layer, resulting in increased EE and LE. Thus, in the case of LCHNP60:20, a higher quantity of DOTAP used could lead to a more robust lipid layer, as verified by the strong, positive $\zeta$-potential. Consequently, the robust layer of DOTAP contributed to the trapping of hydrophilic vancomycin molecules within the LCHNP, resulting in higher EE and LE.

Among LCHNP60:10, LCHNP 60:20, LCHNP120:10, and LCHNP120:20, it was observed that LCHNP60:20 displayed desirable properties required for the delivery of vancomycin into biofilms, whereby: (1) a high value of LE signifying that more antibiotics could be delivered with a small quantity of LCHNPs; (2) a high value of EE indicating that a higher proportion of antibiotic used during fabrication was encapsulated, resulting in lesser wastage; and (3) a positive surface charge which would be beneficial for penetrating into biofilms. Thus, further optimization was carried out based on the formulation for LCHNP60:20, which led to LCHNP45:20 and LCHNP30:20.

It was noted that LCHNP45:20 had the highest EE, LE, and $\zeta$-potential of 48.66%, 72.99 $\mu$g/mg and $+36.13$ mV, respectively (Figure 1a–c). These measurements were significantly higher than those of LCHNP60:20 and LCHNP30:20. In fact, the LE of the optimized LCHNP45:20 was significantly higher than the widely reported values of 2.6–15.8 $\mu$g/mg for reported nanoparticulate systems used to encapsulate hydrophilic molecules. Thus, the formulation for LCHNP45:20 was chosen for subsequent experiments.

2.2. Physical Characterization of Optimized LCHNPs and Comparison with PLGANPs. To determine the role of DOTAP in the nanoparticulate systems, bare and vancomycin-loaded PLGANPs were fabricated using the exact same parameters as those used for the fabrication of the optimized LCHNPs, less DOTAP. Through dynamic light scattering, the hydrodynamic diameters of both PLGANPs and LCHNPs were determined to be $221.03 \pm 6.50$ and $207.83 \pm 2.06$ nm, respectively (Figure 2a). The sizes of these nanoparticles fall within the desirable range of 100–500 nm for penetration into biofilms through water channels and EPS without eliciting rapid clearance by the host. LCHNPs were observed to be significantly smaller ($^{**}$) than the bare PLGANPs. This was likely due to the presence of the cationic DOTAP, which played a crucial role in regulating the size of LCHNPs, preventing the coalescence of these nanoparticles. The drastic difference in $\zeta$-potentials of PLGANPs and LCHNPs ($-36.83 \pm 1.24$ and $36.13 \pm 0.31$ mV, respectively) suggested that DOTAP was successfully coated onto the PLGA core of LCHNPs. The field-emission scanning electron microscopy (FESEM) images (Figure 2b,c) showed the spherical
The core–shell structure of LCHNPs was further verified using transmission electron microscopy (TEM) (Figure 2d). The EE and LE values of LCHNPs were significantly improved over those of PLGANPs. The addition of the DOTAP layer on the PLGA surface possibly prevented vancomycin molecules from escaping out of the nanoparticles during fabrication, leading to higher EE and LE. Given that vancomycin is highly hydrophilic, there is a high tendency of it escaping from the oil phase of the emulsion into the bulk aqueous phase during the fabrication process. This could be observed from the lower EE and LE values of PLGANPs of Figure 2.

### Table 1: Physicochemical Characteristics of PLGANPs and LCHNPs

| Sample  | Hydrodynamic Diameter (nm) | Polydispersity Index | ζ-potential (mv) | EE%    | LE (μg/mg) |
|---------|----------------------------|----------------------|------------------|--------|------------|
| PLGANPs | 221.03 ± 6.50              | 0.29 ± 0.03          | -36.83 ± 1.24    | 24.11 ± 0.64 | 52.25 ± 1.38 |
| LCHNPs  | 207.83 ± 2.06              | 0.24 ± 0.04          | 36.13 ± 0.31     | 48.66 ± 0.42 | 72.99 ± 0.63 |

**Figure 2.** Comparison of optimized LCHNPs against bare PLGANPs. (a) Summary of physicochemical characteristics (hydrodynamic diameter and ζ-potential), EE, and LE of PLGANPs and LCHNPs; (b) FESEM micrograph of PLGANPs; (c) FESEM micrograph of LCHNPs; (d) TEM micrograph of LCHNPs; and (e) vancomycin release profile of Van-PLGANPs and Van-LCHNPs.

morphologies of both PLGANPs and LCHNPs. The core–shell structure of LCHNPs was further verified using transmission electron microscopy (TEM) (Figure 2d). The EE and LE values of LCHNPs were significantly improved over those of PLGANPs. The addition of the DOTAP layer on the PLGA surface possibly prevented vancomycin molecules from escaping out of the nanoparticles during fabrication, leading to higher EE and LE. Given that vancomycin is highly hydrophilic, there is a high tendency of it escaping from the oil phase of the emulsion into the bulk aqueous phase during the fabrication process. This could be observed from the lower EE and LE values of PLGANPs of Figure 2.
24.11 ± 0.64% and 52.25 ± 1.38 μg/mg, respectively. On the other hand, LCHNPs had an EE of 48.66 ± 0.42% and LE of 72.99 ± 0.63 μg/mg, highlighting the essential role of the lipid layer in achieving high EE and LE of hydrophilic molecules in polymeric nanoparticles. Furthermore, the lipid layer was observed to retard the release of vancomycin from the nanoparticles. From the release profiles (Figure 2e), 43.93% of the encapsulated vancomycin within Van-LCHNPs was released, while 92.26% of the drug was released from Van-PLGANPs. The burst release of vancomycin from both types of nanoparticles within the first 24 h was not unexpected, given that the hydrophilic vancomycin would tend to localize at the surface of the hydrophobic nanoparticles. Nonetheless, vancomycin release data within the first 24 h suggested that the presence of the lipid layer mitigated the burst release of vancomycin. This was in good agreement with Sivadasan et al. who suggested that the presence of a lipid shell on nanoparticulate carriers reduced the rate of water penetration, resulting in a reduced rate of hydrolysis of the polymeric core and thus, a slower rate of release.

2.3. Presence of the DOTAP Layer Enhanced Antibacterial Efficacy against Planktonic USA300. Prior studies had demonstrated the effectiveness of positively charged drug delivery systems, such as cationic liposomes and certain antimicrobial peptides, on making first contact and continuous binding with bacteria. Therefore, it was hypothesized that Van-LCHNPs, being positively charged, would have an enhanced therapeutic effect against planktonic USA300 compared to bare Van-PLGANPs. Comparing against Free-Van, it was observed that Van-LCHNPs exhibited enhanced antibacterial effects against planktonic USA300 (Figure 3). Based on Figure 3, it was determined that the minimum inhibitory concentration (MIC) and minimum biocidal concentration (MBC) of Van-LCHNPs were 0.58 and 1.16 μg/mL, respectively, which were at least a sixfold reduction as compared to the MIC and MBC values for Free-Van (4.64 and 9.28 μg/mL, respectively). This contrasted with the case for Van-PLGANPs whereby MIC and MBC values increased. At 1.16 μg/mL of vancomycin exposure, Van-LCHNPs were able to reduce the number of CFUs from 8.89 × 10^8 CFU/mL (untreated control) to the limit of detection of 3.33 × 10^5 CFU/mL, implying a reduction of at least 3 logs (or 99.9%). On the other hand, at the same concentration of vancomycin exposure, there were no significant CFU reduction effect observed from Free-Van and Van-PLGANPs (1.11 × 10^8 and 6.89 × 10^6 CFU/mL, respectively). The poor antibacterial efficacy of Van-PLGANPs was likely due to PLGANPs having poor interactions with the USA300 cells owing to the negative charge on both. Arakha et al. reported that negatively charged nanoparticles do not adhere to bacteria owing to poor electrostatic attraction. Furthermore, the controlled release of vancomycin from Van-PLGANPs implied that inhibitory or biocidal concentrations of vancomycin could not be reached quickly, ultimately resulting in higher MIC and MBC values as compared to Free-Van. To eliminate the possibility that the enhanced bacterial effects of LCHNPs were caused directly by the intrinsic antibacterial property of the nanoparticles, blank LCHNPs and PLGANPs were utilized as controls; data from these blank runs showed that no antibacterial effects were observed from extremely high nanoparticle concentrations up to 10,000 μg/mL (data not shown). The stronger antibacterial effect of Van-LCHNPs in comparison to Van-PLGANPs could be due to the presence of the cationic DOTAP layer playing a significant role in allowing the LCHNPs to make first contact and continuous binding with the USA300 cells. This is in good agreement with Costa et al. who correlated the positive effect of enhancing interactions between nanoparticles and bacterial cells on antibiotic delivery.

2.4. Enhanced Antibiofilm Effect against USA300 Biofilms Using LCHNPs. To evaluate the capability of LCHNPs to eradicate USA300 biofilms, static biofilms were cultivated in 8-well chambered coverglasses. The cultivated biofilms were then treated overnight with Free-Van, Van-PLGANPs, and Van-LCHNPs with vancomycin concentrations ranging from 256 to 0.25 μg/mL in 4-fold dilutions. Through crystal violet staining, remnant biofilms following treatment could be visually observed (Figure 4a–c). It was observed that Free-Van and Van-PLGANPs did not cause any
significant reduction in biomass across all tested concentrations as compared to the untreated controls. This suggested that both groups were not able to sufficiently eradicate the underlying bacterial cells to cause any biofilm disruption. On the other hand, significant reductions in biomass were observed for Van-LCHNPs, specifically for vancomycin concentrations of 256–4 μg/mL. It should be noted that vancomycin concentrations of 256 and 64 μg/mL for Van-LCHNPs corresponded to higher concentrations of nanoparticles that were used for treatment. The high concentrations

Figure 4. Assessment of the biofilm eradication capabilities of Free-Van, Van-PLGANPs, and Van-LCHNPs. Crystal violet staining was performed post-treatment for visual observation of remaining biomass as pictured in (a) Free-Van, (b) Van-PLGANPs, and (c) Van-LCHNPs. CFU counts that were derived from the remaining biofilm are shown in (d); horizontal line at ∼2 × 10^10 denotes the CFU counts derived from untreated biofilm controls. Significant differences between groups were analyzed using Mann–Whitney test on OriginPro 2021 (*P < 0.05, n = 4).
led to residual nanoparticles that were not completely removed during the washing step in the protocol which subsequently led to the observed signals following crystal violet staining which should not be incorrectly interpreted as biomass. The observations from crystal violet staining were supported with CFU data that were derived from remnant biofilms. As observed from Figure 4d, Van-LCHNPs exhibited an exceptional capability to eradicate USA300 biofilms across all tested concentrations of vancomycin. At 256 μg/mL, Van-LCHNPs showed the highest degree of biofilm cell eradication with 4 logs reduction (or 99.99%) in CFU/mL as compared to the untreated control (∼2 × 10^10 CFU/mL). Even at 0.25 μg/mL of vancomycin, Van-LCHNPs could reduce the CFU count by 2 logs (99%). On the other hand, Free-Van and Van-PLGANPs were largely incapable of meaningfully reducing the CFU counts in USA300 biofilms. This suggested that Free-Van and Van-PLGANPs could not adequately penetrate through the biofilms for vancomycin to be taken up by the underlying bacterial cells. We postulated that the strong antibiofilm capability of Van-LCHNPs is due to the presence of the DOTAP coating which enhanced interactions between the nanoparticles and the biofilm EPS, leading to enhanced penetration. Wang et al. suggested that the utilization of lipids which are chemically similar to bacterial membranes could improve the fusion of nanoparticles with bacterial cells. Furthermore, Sugano et al. reported that cationic liposomes do not only interact well with planktonic bacterial cells, but also biofilms. This was due to electrostatic interactions between the cationic liposomes and the biofilm matrix, which are often negatively charged. Consequently, Van-LCHNPs, coated with cationic DOTAP, were able to penetrate deeper into the biofilms to deliver the antibiotics directly to the USA300 cells.

2.5. Enhanced Antibiofilm Capability of LCHNPs Could Prevent Recalcitrant Infections. A key challenge in treating biofilm infections arises from the fact that it is hard for antibiotics or antibiotic delivery systems to penetrate deeply into biofilms to eradicate the underlying cells uniformly throughout the entire thickness of the biofilm. Even if killing occurs, biofilm cells may not be sufficiently eradicated, and the biofilm matrix remains intact. This often gives rise to recalcitrant infections as biofilms which are not completely removed often become a starting point for biofilm regrowth. From Figure 4c, it was observed that there was little biomass remaining following treatment with Van-LCHNPs corresponding to 4–256 μg/mL, suggesting that biofilms were removed. To verify this, confocal microscopy was performed following treatment to image the remaining biofilms. The biofilms were stained with Syto9 and propidium iodide (PI) prior to imaging. Figure 5a shows the confocal microscopy images for each sample group. When biofilms were treated with Free-Van (0.25–16 μg/mL), the confocal images showed that the bulk of the biofilm cells were alive (green signals) even though the tested concentrations exceeded the MBC of vancomycin required to completely eradicate planktonic USA300 cells.
Also, digital measurement of the biofilm thicknesses (Figure 5b) showed that biofilms treated with Free-Van had increased in thickness as compared to the untreated control. The increase in biofilm thickness with the observations reported by Hsu et al. that the use of vancomycin on S. aureus biofilms promoted bacterial autolysis. As a result, biomolecules leaking from the lysed cells may be retained in the biofilm, leading to an increase in biofilm thickness. For Van-PLGANPs, only at concentrations corresponding to 4 and 16 μg/mL of vancomycin exhibited any antibacterial effect toward the biofilm cells. The killing of biofilm cells at 4 μg/mL appeared to be closer to the top surface of the biofilm, while biofilm cells residing deeper remained alive. At 16 μg/mL, the biofilm cells appeared to be eradicated throughout the thickness of the biofilm. However, the biofilm remained intact and could lead to regrowth of the biofilm. For Van-LCHNPs, the thickness of the biofilms appeared to be significantly reduced across all four concentrations that were imaged. The degree of biofilm removal was most pronounced at concentrations of 1, 4, and 16 μg/mL. Antibiofilm effects appeared to be dose-dependent, whereby the dead cells appeared to be distributed throughout the remaining thickness of the biofilms for 4 and 16 μg/mL. Overall, the data suggested that Van-LCHNPs possessed excellent antibiofilm ability as it could eradicate the underlying cells and cause biofilm removal.

2.6. Presence of a Robust Coating of DOTAP Led to Enhanced Penetration Ability of LCHNPs into USA300 Biofilms. It was verified through several methods that Van-LCHNPs possessed exceptional antibiofilm ability over Free-Van and Van-PLGANPs (Figures 4 and 5). This study stemmed from the hypothesis that the presence of a cationic lipid coating could enhance the penetration of nanoparticles into biofilms, leading to improved antibiofilm capabilities. To verify the role of DOTAP coating in enabling enhanced penetration into biofilms, PI-loaded LCHNPs of various DOTAP:PLGA ratios were fabricated. These PI-loaded nanoparticles were then incubated overnight with USA300 biofilms prior to confocal microscopy imaging. By utilizing the Z-stack function of the confocal microscope, it was investigated how deep into the biofilms these nanoparticles were able to penetrate.

Confocal images (Figure 6) showed that nanoparticles with a DOTAP:PLGA ratio of 0:45 (equivalent to PLGANPs) exhibited poor penetration into USA300 biofilms while penetration into biofilms increased gradually as the DOTAP:PLGA ratio was increased from 0:45 to 20:45. This could be observed from the increase in red signals coming from the PI-loaded nanoparticles as the DOTAP:PLGA ratio was increased. This suggested that the DOTAP:PLGA ratio and the degree of penetration into biofilms had a dose−response relationship, implying that the DOTAP coating played a causal role in allowing the LCHNPs to penetrate deeply into the biofilms. To the best knowledge of the authors at the time of writing, this is the first time that a cationic lipid coating is shown to directly enhance the penetrating capability of nanoparticles, especially for LCHNPs, into biofilms.

The penetration of LCHNPs into biofilms could be described using the nanoparticle–biofilm transport phenomena. First, nanoparticles must be transported to the biofilm−fluid interface; second, the nanoparticles must attach to the outer surface of the biofilms; lastly, the nanoparticles would have to migrate into the biofilm. Interactions with the biofilm EPS are often governed by the surface properties of the nanoparticles, such as surface charge and functional groups present on the surface. These interactions are critical for nanoparticles to establish first contact required with the biofilm surface before the nanoparticles could migrate into the biofilms. In the case of LCHNPs in this study, a strongly positive-charged surface was presented to the biofilm EPS, allowing for strong interactions between the negatively charged EPS components and the LCHNPs. This contrasts with PLGANPs, which present a negatively charged surface and thus, have poor interactions with the biofilm EPS. This observation is congruent with studies that reported that electrostatic interactions played a critical role in determining the ability of nanoparticles to adhere onto biofilm surfaces.

3. CONCLUSIONS

In this study, the fabrication of LCHNPs was optimized, resulting in nanoparticles which demonstrated high LE and EE of vancomycin. The antibacterial and antibiofilm effects of Van-LCHNPs were studied and compared against Free-Van and Van-PLGANPs. In vitro tests against planktonic and biofilm USA300 showed that LCHNPs demonstrated enhanced antimicrobial effects. In particular, LCHNPs exhibited exceptional antibiofilm ability by killing off biofilm cells and facilitated the removal of the biofilm matrix. The removal of the biofilm matrix is crucial for preventing recalcitrant infections. Finally, for the first time, we showed that the presence of a cationic lipid layer on LCHNPs directly enhanced the penetrating capability of the nanoparticles into USA300 biofilms. Given that biofilms are extremely complex and dynamic in nature, the interactions of nanoparticles with biofilms are still not well understood. With further investigations into the interactions between nanoparticles and biofilms, LCHNPs could be optimized to further enhance their capability to eradicate biofilms.

4. MATERIALS AND METHODS

4.1. Materials. Resomer RG 502 H poly(D,l-lactide-co-glycolide) (PLGA, MW = 7−17 kDa, acid-terminated), poly(vinyl alcohol) (PVA, MW = 30−80 kDa, 87% hydrolyzed), Span 80, and vancomycin hydrochloride were purchased from Sigma-Aldrich. 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP, chloride salt) was purchased from Avanti Lipids. Unless stated otherwise, all solvents used were of analytical grade and purchased from Sigma-Aldrich. High-

Figure 6. Confocal microscopy images showing the degrees of penetration of LCHNPs fabricated with varying ratios of DOTAP:PLGA.
performance liquid chromatography (HPLC)-grade solvents used for HPLC mobile phases were purchased from Tedia.

### 4.2. Fabrication and Optimization of LCHNPs
Blank LCHNPs were fabricated using an oil-in-water (O/W) single emulsion solvent evaporation technique. The organic phase was prepared by dissolving 45 mg of PLGA and 20 μL of Span 80 in 2 mL of dichloromethane (DCM). The aqueous phase was prepared by suspending 20 mg of DOTAP into 20 mL of 1% w/v PVA solution (in 0.95% MES buffer, pH 6.9). Under probe sonication on an ice bath at 40% amplitude, the organic phase was added into the aqueous phase to form an emulsion and sonicated for 1 min. Subsequently, primary W/O/W emulsion was obtained by adding 400 μL of vancomycin solution to the organic phase and probe-sonicated at 40% amplitude for 12 cycles in pulse mode (3 s on, 2 s off). Following sonication, the primary emulsion was left to stir at 1000 rpm for 4 h to evaporate the DCM. Following evaporation, the resulting solution was washed thrice by centrifugation at 18 k rpm for 12 min to remove excess precursors, such as PVA and vancomycin. After the final wash, the resulting pellet was frozen and lyophilized to obtain LCHNP powder.

To fabricate vancomycin-loaded LCHNPs (Van-LCHNP), a water-in-oil-in-water (W/O/W) double emulsion solvent evaporation approach was utilized. Vancomycin solution was prepared by dissolving vancomycin hydrochloride powder in 1% w/v PVA (in 0.95% MES buffer, pH 6.9) at a concentration of 24.375 mg/mL. The primary W/O emulsion was formed by adding 400 μL of vancomycin solution to the organic phase and probe-sonicated at 40% amplitude for 12 cycles in pulse mode (3 s on, 2 s off). Subsequently, the secondary W/O/W emulsion was obtained by adding the primary emulsion into the secondary aqueous phase and sonicated at 40% amplitude for 1 min. Following sonication, the emulsion was allowed to stir at 1000 rpm for 4 h to evaporate the DCM, and subsequently washed thrice by centrifugation at 18 k rpm for 12 min. Washing was necessary to remove excess, unencapsulated vancomycin from the LCHNPs. The resulting pellet was frozen and lyophilized to obtain Van-LCHNP powder.

For the fabrication of blank and vancomycin-loaded control nanoparticles, DOTAP was removed from the abovementioned formulation to form blank and Van-PLGANP powder.

### 4.3. Characterization of LCHNPs
The hydrodynamic diameters and zeta potentials (ζ-potential) of LCHNPs were measured by dynamic light scattering using a Malvern Zeta Sizer ZS. Briefly, lyophilized powder of LCHNPs was dispersed in deionized H2O to obtain 1 mg/mL suspensions, which were then added into a Malvern disposable folded capillary cell (DTS1070) and inserted into the equipment for measurements to be taken. For FESEM, the sample was prepared by applying a thin layer of LCHNP dry powder onto carbon tape. This was followed by sputter-coating the layer with Pt for 15 s after which the sample was then imaged under JEOL FESEM 7600 F at 2 kV acceleration voltage with a probe current of 8. For TEM, freshly fabricated LCHNP suspension was added onto lacy carbon copper grids for 2 min followed by staining with 5 μL of UranyLess solution for 3 min. The resulting sample was then imaged using JEOL 2010HR with an acceleration voltage of 200 kV.

### 4.4. Vancomycin Loading Measurement
Ten milligrams of lyophilized Van-PLGANP and Van-LCHNP powder were dissolved in 1 mL of dimethyl sulfoxide (DMSO) and filtered through a 0.22 μm pore size syringe filter. HPLC with a UV−vis detector was used to detect and measure the quantity of vancomycin in the solution. The analyte was passed through a C18 column (Zorbax SB, 5.0 μm, 4.6 × 250 mm) and the absorbance at 282 nm was measured for the detection of vancomycin. In the presence of an absorption peak, the peak area was correlated to the concentration of vancomycin in the analyte using a simple linear regression model with the appropriate standard solutions. To calculate EE% and LE, the following equations were used for calculation:

\[
EE\% = \frac{\text{Mass of antibiotic encapsulated}}{\text{Total mass of antibiotic used in fabrication}} \times 100\%
\]

\[
LE (\mu g/mg) = \frac{\text{Mass of antibiotic encapsulated}}{\text{Mass of LCHNP used}}
\]

### 4.5. In Vitro Drug Release
In vitro release study was performed using dialysis technique. Briefly, 20 mg of sample powder were suspended in 5 mL of tryptic soy broth (TSB) and transferred into a dialysis bag (3 kDa cut-off). The dialysis bag was then immersed in 50 mL of TSB and allowed to stir at 200 rpm. Two milliliters of release medium were collected at predetermined timepoints and replaced with fresh TSB medium. The amount of antibiotic released was measured using HPLC UV−vis.

### 4.6. Bacterial Strain and Growth Conditions
MRSA USA300 strain was used as the model pathogen in this study. A defrost glycerol stock of USA300 was plated on tryptic soy agar (TSA) and incubated overnight at 37 °C to obtain single colonies. Prior to each experiment, a single colony was inoculated into 10 mL of fresh TSB and incubated overnight at 37 °C for 24 h.

### 4.7. Antibiotic Susceptibility Test on Planktonic USA300
The MIC and MBC were determined using the broth dilution method adapted from Wiegand et al. Briefly, the overnight culture of USA300 was washed thrice with PBS using centrifugation (8000 rpm, 5 min), and diluted to an optical density of 0.2 at 600 nm in TSB. This corresponds to 1 × 10^8 CFU/mL of planktonic USA300 cells. The sample groups tested in this experiment include free vancomycin (Free-Van), Van-PLGANP, and Van-LCHNP. In sterile 96-well plates, twofold serial dilutions were performed for each sample group such that the concentrations of vancomycin, both free and released from nanoparticles, ranged from 0.25–128 μg/mL. Finally, 100 μL of the diluted bacterial culture were added into each well, resulting in a final bacterial concentration of about 5 × 10^7 CFU/mL. Blank PLGANP and LCHNP were also tested in concentrations that were significantly higher than Van-PLGANP and Van-LCHNP to determine if these control particles possessed any intrinsic antibacterial properties. Controls containing only bacteria (untreated) or medium without cells (blank) were also tested. The 96-well plates were then incubated overnight in a 37 °C, 5% CO_2 incubator for 24 h. Following incubation, the optical densities at 600 nm of each well were measured using Tecan Microplate Reader M200. Subsequently, selected wells were plated onto TSA to determine the MBC. The MIC was defined as the lowest concentration of vancomycin which prohibits planktonic bacterial growth, corresponding to an optical density difference of less than 10% from the control. The MBC was defined as the lowest concentration of vancomycin required to completely eradicate the USA300 planktonic cells as observed from the TSA plates.

### 4.8. In Vitro Antibiofilm Test
The abilities of Free-Van, Van-PLGANP, and Van-LCHNP to eradicate biofilm cells
were evaluated in this study. To culture biofilms, an overnight culture of USA300 was washed thrice with PBS (8000 rpm, 5 min) and diluted in TSB supplemented with 1% w/v glucose and 50 μg/mL of methicillin. The addition of 1% w/v glucose and 50 μg/mL methicillin was necessary to form robust biofilms capable of withstanding the multiple washing steps during the experiments. 500 μL of the diluted culture (OD<sub>600</sub> = 0.4) were added into each well of an 8-well chambered coverglass (Nunc Lab-Tek II) and allowed to incubate overnight in a 37 °C, 5% CO<sub>2</sub> incubator for 24 h. Following incubation, the supernatant in each well was disposed and each well was washed once with PBS to remove any residual planktonic cells. This was followed by adding 500 μL of FreeVan or equivalent concentrations of NP suspensions into each well, ranging from 0.25 to 256 μg/mL of vancomycin in fourfold serial dilutions. Once the necessary treatment and control groups were added, the chambered coverglasses were incubated overnight. Following treatment, the supernatant in each well was disposed and washed once with PBS to remove residual planktonic cells and nanoparticles following which different characterization methods were employed to observe the antibiofilm efficacies of each treatment group. First, for post-treatment visual observations of the remaining biofilms, if any, 500 μL of 0.1% w/v crystal violet was added into each well. The wells were allowed to sit for 15 min for crystal violet to stain the biofilms after which the crystal violet supernatant was disposed, and each well was washed twice with PBS. Second, to observe if any killing of biofilm cells took place throughout the treatment. The stained biofilms were then imaged using confocal scanning laser microscopy (CLSM, Zeiss LSM780). Excitation lasers were 442 nm for Syto9-labeled cells and 561 nm for PI-labeled cells. Finally, to determine the CFU reduction for each treatment group, any residual biofilms in the wells post-treatment were resuspended in TSB through rigorous pipetting. The suspensions were then plated onto TSA plates and incubated overnight after which the CFU reduction could be determined.

4.9. Determining Biofilm-Penetrating Capabilities of LCHNPs. The ability of LCHNPs to penetrate biofilms was evaluated using CLSM. Instead of antibiotics, each LCHNP group was loaded with PI. To determine the effect of the lipid layer on biofilm penetration, PI-loaded LCHNPs, with various DOTAP-to-PLGA ratios, were fabricated. To prepare the specimens for CLSM imaging, 2.5 mg/mL of the PI-loaded NP suspensions were added into biofilm-cultivated wells and allowed to incubate overnight. This was followed by washing off any loose nanoparticles with PBS, and staining the biofilms with Syto9, prior to CLSM imaging.

**AUTHOR INFORMATION**

**Corresponding Author**

Say Chye Joachim Loo — School of Materials Science & Engineering, Nanyang Technological University, Singapore 639798, Singapore; Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 637551, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore; orcid.org/0000-0001-5300-1275; Email: joachimloo@ntu.edu.sg

**Authors**

Hiang Wee Lee — School of Materials Science & Engineering, Nanyang Technological University, Singapore 639798, Singapore; orcid.org/0000-0003-3756-5040

Sharad Kharel — School of Materials Science & Engineering, Nanyang Technological University, Singapore 639798, Singapore

Complete contact information is available at: https://pubs.acs.org/10.1021/acsomega.2c04008

**Author Contributions**

H.W.L. designed the work, performed experiments, analyzed data, and wrote the original draft. S.K. performed TEM, analyzed the associated data, and revised the draft. S.C.J.L. supervised the work and revised the draft. All authors read and approved the final manuscript.

**Funding**

This project was supported by funding from the Singapore Centre of Environmental Life Sciences Engineering (SCELE) (MOE/RCE: M4330019.C70), Ministry of Education AcRF Tier 1 grant (RG19/18 and RT08/19), the Singapore National Biofilm Consortium (SNBC/2021/SF2/P04), and the Singapore Food Agency (SFS_RND_SUF_P001_06).

**Notes**

The authors declare no competing financial interest. All data generated or analyzed during this study are included in this published article.

**ACKNOWLEDGMENTS**

The authors would like to acknowledge the Advanced Biofilm Imaging Facility (ABIF) at SCELE for providing the Zeiss LSM780 CLSM platform used in this study, and especially Dr. Radek Machán and Dr. Yong Hwee Foo for rendering the technical assistance required.

**REFERENCES**

(1) Antibiotic resistance threats in the United States, 2019, 2019.

(2) O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations, 2016.

(3) Joo, H. S.; Otto, M. Molecular basis of in vivo biofilm formation by bacterial pathogens. Chem. Biol. 2012, 19, 1503–1513.

(4) Roy, R.; Tiwari, M.; Donelli, G.; Tiwari, V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence 2018, 9, 522–554.

(5) Olivares, E.; Badel-Berchoux, S.; Provot, C.; Prévost, G.; Bernardi, T.; Jehl, F. Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections. Front. Microbiol. 2020, 10, 2894.

(6) Wille, J.; Coenye, T. Biofilm dispersion: The key to biofilm eradication or opening Pandora’s box? Biofilm 2020, 2, No. 100027.

(7) Baek, J.-S.; Tan, C. H.; Ng, N. K. J.; Yeo, Y. P.; Rice, S. A.; Loo, S. C. J. A programmable lipid-polymer hybrid nanoparticle system for localized, sustained antibiotic delivery to Gram-positive and Gram-negative bacterial biofilms. Nanoscale Horiz. 2018, 3, 305–311.

(8) Li, J.; Zhong, W.; Zhang, K.; Wang, D.; Hu, J.; Chan-Park, M. B. Biguanide-Derived Polymeric Nanoparticles Kill MRSA Biofilm and Suppress Infection In Vivo. ACS Appl. Mater. Interfaces 2020, 12, 21231–21241.

(9) Gajdács, M. The Continuing Threat of Methicillin-Resistant Staphylococcus aureus. Antibiotics 2019, 8, 52.

(10) Ma, Y.-X.; Wang, C.-Y.; Li, Y.-Y.; Li, J.; Wan, Q.-Q.; Chen, J.-H.; Tay, F. R.; Niu, L.-N. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Adv. Sci. 2019, 7, 1901872–1901872.
(11) De Oliveira, D. M. P.; Forde, B. M.; Kidd, T. J.; Harris, P. N. A.; Schembri, M. A.; Beatson, S. A.; Paterson, D. L.; Walker, M. J. Antimicrobial Resistance in ESKAPE Pathogens. *Clin. Microbiol. Rev.* 2020, 33, No. e00181-19.

(12) Jiang, L.; Lee, H. W.; Loo, S. C. J. Therapeutic lipid-coated hybrid nanoparticles against bacterial infections. *RSC Adv.* 2020, 10, 8497–8517.

(13) Yeh, Y.-C.; Huang, T.-H.; Yang, S.-C.; Chen, C.-C.; Fang, J.-Y. Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances. *Front. Chem.* 2020, 8, 286.

(14) Tan, C. H.; Jiang, L.; Li, W.; Chan, S. H.; Baek, J.-S.; Ng, N. K. J.; Sailov, T.; Kharel, S.; Chong, K. K. L.; Loo, S. C. J. Lipid-Polymer Hybrid Nanoparticles Enhance the Potency of Ampicillin against *Enterococcus faecalis* in a Protozoa Infection Model. *ACS Infect. Dis.* 2021, 7, 1607–1618.

(15) Ismail, R.; Sovány, T.; Gácsi, A.; Ambrus, R.; Katona, G.; Imre, N.; Csóka, I. Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery. *Pharm. Res.* 2019, 36, 99.

(16) Ramalho, M. J.; Loureiro, J. A.; Coelho, M. A. N.; Pereira, M. C. Factorial Design as a Tool for the Optimization of PLGA Nanoparticles for the Co-Delivery of Temozolomide and O6-Benzyguanine. *Pharmaceuticals* 2019, 11, 401.

(17) Seedat, N.; Kalhupure, R. S.; Mocktar, C.; Vepuri, S.; Jadhav, M.; Soliman, M.; Govender, T. Co-encapsulation of multi-lipids and polymers enhances the performance of vancomycin in lipid-polymer hybrid nanoparticles: In vitro and in silico studies. *Mater. Sci. Eng., C* 2016, 61, 616–630.

(18) Liu, Y.; Pan, J.; Feng, S. S. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. *Int. J. Pharm.* 2010, 395, 243–250.

(19) Sonawane, S. J.; Kalhupure, R. S.; Rambarrose, S.; Mocktar, C.; Vepuri, S. B.; Soliman, M.; Govender, T. Ultra-small lipid-dendrimer hybrid nanoparticles as a promising strategy for antibiotic delivery: In vitro and in silico studies. *Int. J. Pharm.* 2016, 504, 1–10.

(20) Sabaeifard, P.; Abdi-Ali, A.; Soudi, M. R.; Gamazo, C.; Irache, J. M. Amikacin loaded PLGA nanoparticles against Pseudomonas aeruginosa. *Eur. J. Pharm. Sci.* 2016, 93, 392–398.

(21) Durati, R.; DeTrizio, A.; Spell, M.; Migliavacca, R.; Pagani, L.; Pisani, S.; Chiesa, E.; Conti, B.; Modena, T.; Genta, I. Gentamicin Sulfate PEG-PLGA/PLGA-H Nanoparticles: Screening Design and Antimicrobial Effect Evaluation toward Clinic Bacterial Isolates. *Nanomaterials* 2018, 8, 37.

(22) Liu, Y.; Shi, L.; Su, L.; van der Mei, H. C.; Jutte, P. C.; Ren, Y.; Busscher, H. J. Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control. *Chem. Soc. Rev.* 2019, 48, 428–446.

(23) Ghitman, J.; Biru, E. I.; Stan, R.; Iovu, H. Review of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine. *Mater. Des.* 2020, 193, No. 108805.

(24) Sivadasan, D.; Sultan, M. H.; Madkhali, O.; Almoshri, Y.; Thangavel, N. Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform-A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications. *Pharmaceutics* 2021, 13, 1291.

(25) Fulaz, S.; Devlin, H.; Vitale, S.; Quinn, L.; O’Gara, J. P.; Casey, E. Tailoring Nanoparticle-Biofilm Interactions to Increase the Efficacy of Antimicrobial Agents Against *Staphylococcus aureus*. *Int. J. Nanomed.* 2020, 15, 4779–4791.

(26) Sugano, M.; Morisaki, H.; Negishi, Y.; Endo-Takahashi, Y.; Kuwata, H.; Miyazaki, T.; Yamamoto, M. Potential effect of cationic liposomes on interactions with oral bacterial cells and biofilms. *J. Liposome Res.* 2016, 26, 156–162.

(27) Arakha, M.; Pal, S.; Samantarrai, D.; Panigrahi, T. K.; Mallick, B. C.; Pramanik, K.; Mallick, B.; Jha, S. Antimicrobial activity of iron oxide nanoparticle upon modulation of nanoparticle-bacteria interface. *Sci. Rep.* 2015, 5, 14813.